Racing against big-name vaccines players, Valneva reported positive Phase II results this week for its GlaxoSmithKline-partnered C. difficile vaccine candidate, saying the shot proved to be “highly immunogenic” while also offering a good safety and a tolerable profile.
The trial, conducted in Germany and the United States, tested the vaccine candidate in 500 volunteers separated into two age groups: 50 to 64 and 65 and above. Researchers reported that the vaccine was immunogenic at all doses and formulations tested, with a high-dose formulation containing no adjuvant generating a superior response.
With the results, the Lyon, France-headquartered company said it’ll announce further development steps after its final Phase II closeout in Q2 2016.
To read this article in its entirety click on the link below:
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.